Online inquiry

IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ29MR)

This product GTTS-WQ29MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ29MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ974MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ7688MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ621MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10533MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1961MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ10673MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ12090MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ15537MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7858
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW